secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001854270-24-000061
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio appoints Kanya Rajangam as President; CEO Lu remains CEO
------------------------------------------------------------------

- Tim Lu stepped down as President effective May 14, 2024, but continues as CEO.
- Kanya Rajangam, M.D., Ph.D., appointed President; she remains Head of R&D and CMO.
- Rajangam joined Senti in July 2022; prior CMO at Nkarta (NKTX) and Atara (ATRA).
- Her compensation includes $490K base salary, 40% target bonus, option grant, and severance per 2022 offer letter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000061/0001854270-24-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000061/snti-20240514.htm
  HTML page:      https://secwatch.observer/filing/0001854270-24-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer